Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 17/20 | 0.45 |
| ▸ | BRD4 | O60885 | 14/20 | 0.45 |
| ▸ | EP300 | Q09472 | 5/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846737 | 0.87 | MAPT (0.47) | MAPTCREBBPBRD4EP300USP30 | |
| SCHEMBL2480874 | 0.85 | MAPT (0.52) | MAPTCREBBPBRD4EP300USP30 | |
| SCHEMBL2558470 | 0.78 | CREBBP (0.46) | CREBBPBRD4EP300 | |
| SCHEMBL2849425 | 0.76 | MAPT (0.43) | MAPTCREBBPBRD4EP300USP30 | |
| SCHEMBL2842312 | 0.72 | CREBBP (0.52) | CREBBPBRD4EP300 | |
| SCHEMBL2847251 | 0.72 | MAPT (0.46) | MAPTCREBBPBRD4GPR119 | |
| SCHEMBL2844793 | 0.70 | MAPT (0.55) | MAPT | |
| SCHEMBL2842290 | 0.69 | MAPT (0.44) | MAPTCREBBPBRD4GPR119 | |
| SCHEMBL2451416 | 0.69 | MAPT (0.51) | MAPTCREBBPBRD4GPR119 | |
| SCHEMBL2447065 | 0.68 | MAPT (0.45) | MAPTCREBBPBRD4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | MAPT 10/4885CREBBP 646/4885BRD4 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.